Pharmaceutical

President Donald Trump has inked a new executive order calling on the HHS’ Administration for Strategic Preparedness and Response to identify and stoc...

Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease drug sodium oligomannate,...

Despite a threat from President Donald Trump early last week that the administration's policy on pharmaceutical tariffs would come “within the next we...

As parent company Maravai rolls out a $50 million cost-savings drive, 90 staffers from its CDMO subsidiary TriLink are also set to lose their jobs, ac...

An analysis of how cancer drugmakers interact with oncologists found, perhaps unsurprisingly, that those interactions are dominated by therapies boast...

Eli Lilly said it has "intensified efforts to align prices across developed countries" in recent months. Besides a new U.K. price hike, Lilly said it...

The Department of Health and Human Services is relaunching a task force focused on the safety of childhood vaccines. The federal panel will be chaired...

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other comp...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead...